Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.58 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.58 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.54 |
| ▸ | KDM5C | P41229 | 1/20 | 0.54 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932793 | 0.82 | KDM4E (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8214164 | 0.82 | KDM5A (0.54) | KDM4EKDM5AKDM5CKDM5BMEN1 | |
| SCHEMBL1197024 | 0.82 | KDM5A (0.54) | KDM4EKDM5AKDM5CKDM5BMEN1 | |
| SCHEMBL2056351 | 0.78 | PDE9A (0.54) | KDM4EKDM5AKDM5CKDM5BALDH1A1 | |
| SCHEMBL2054638 | 0.78 | KDM5A (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13913155 | 0.78 | KDM5A (0.63) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14916649 | 0.77 | PDE9A (0.70) | KDM4EALDH1A1MAPTCSF1RPIM1 | |
| SCHEMBL29901287 | 0.77 | KDM5A (0.58) | KDM5AKDM5CKDM5B | |
| SCHEMBL20870083 | 0.77 | KDM5A (0.58) | KDM5AKDM5CKDM5B | |
| SCHEMBL404810 | 0.76 | GRIN2D (0.63) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030002-A2 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118946556-A | DGK targeting compounds and uses thereof | 阿维纳斯运营公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-3496716-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| EP-3496716-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | Merck Sharp & Dohme Corp. (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018034918-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2773619-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| CN-103906735-A | Novel aryl-quinoline derivatives | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | FABP1, FABP4, FABP5 | GRIN2D 4238/4885GRIN3B 4299/4885GRIN1 4029/4885 |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | FABP1, FABP4, FABP5 | GRIN2D 4094/4885GRIN3B 4216/4885GRIN1 3986/4885 |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | GRIN2D 4860/4885GRIN3B 4547/4885GRIN1 3718/4885 |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | CYP27A1, CYP7B1, SLC10A1 | GRIN2D 4855/4885GRIN3B 4517/4885GRIN1 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.